

## **KINAXO announces agreement with UCB**

*Martinsried, Germany, November 6, 2006.* KINAXO Biotechnologies GmbH announced today that it has entered into a services and collaboration agreement with UCB S.A. of Brussels, Belgium (UCB). Under the agreement, KINAXO will employ the KinaTor™ technology to perform selectivity analyses for several of UCB's small molecule lead compounds in cells and tissue samples.

"We are very pleased with this collaboration to support UCB's lead optimisation programmes," said Dr. Andreas Jenne, CEO of KINAXO. "We will apply our chemical proteomics technology KinaTor™ to assist UCB in the development of drugs with well-characterized inhibition profiles."

### **About KinaTor™**

The KinaTor™ technology uses immobilized small molecule inhibitors to detect their protein binding partners in biological samples. Small molecule-protein interactions are identified by a combination of sophisticated affinity-based separation procedures and sensitive mass spectrometry. The KinaTor™ provides tailor-made solutions for various applications, such as the identification of previously unknown disease-relevant targets as well as off-target related toxicities.

### **About KINAXO**

KINAXO Biotechnologies is a privately-held biotechnology company based in Munich/Martinsried, Germany. We support pharmaceutical and biotechnology companies in their development and optimization of drugs.

As a spin-off of the Max-Planck Institute of Biochemistry in Martinsried, KINAXO offers extensive experience and a proven track record in cellular kinase profiling with several pharmaceutical and biotechnology company collaborations ongoing, i.e. UCB Pharma, Johnson & Johnson and Takeda. KINAXO is financed by European investors BioM, High-Tech Gründerfonds, KfW, Max Planck Society, and Mountain Partners.

### **About UCB**

UCB ([www.ucb-group.com](http://www.ucb-group.com)) is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing over 8,300 people in over 40 countries, UCB achieved revenue of 2.3 billion Euro in 2005. UCB is listed on the Euronext Brussels Exchange and its worldwide headquarters are located in Brussels, Belgium.

### **Contact**

Dr. Andreas Jenne, CEO  
KINAXO Biotechnologies GmbH  
Am Klopferspitz 19a  
82152 Martinsried, Germany  
[www.kinaxo.com](http://www.kinaxo.com)

Phone: +49 89 700763 831

Email: [info@kinaxo.de](mailto:info@kinaxo.de)